Which segment accounted for the largest North America Hepatitis Testing/Diagnosis Market share?

In terms of applications, the hospitals and diagnostic laboratories segment accounted for the largest market share. These facilities are major users of hepatitis diagnostic tests due to the high influx of patients and advanced healthcare infrastructure, enabling them to deliver rapid and reliable test results for early disease management.

What are the factors driving the North America Hepatitis Testing/Diagnosis Market?

Key drivers include the increasing incidence of hepatitis B and C infections and strong government initiatives for disease awareness. For example, Roche has partnered with public health agencies to expand access to testing, while rising investments in advanced molecular diagnostics are accelerating market expansion.

Which type accounted for the largest North America Hepatitis Testing/Diagnosis Market share?

Among test types, the ELISA (Enzyme-Linked Immunosorbent Assay) segment accounted for the largest market share. ELISA-based tests are widely adopted in clinical and research settings due to their high sensitivity and specificity, cost-effectiveness, and ability to process large sample volumes efficiently.

Home Healthcare

North America Hepatitis Testing/Diagnosis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Hepatitis Testing/Diagnosis Market
Brand: Bussiness Insights

North America Hepatitis Testing/Diagnosis Market: by Type (Hepatitis B, Hepatitis C, Hepatitis A, Hepatitis D, Hepatitis E, Others), Application (Blood Banks, Hospitals & Clinics, Diagnostic Laboratories, Research Institutes, Others), Distribution Channels (Direct Tender, Retail Sales, Online Sales, Others), Technology (ELISA, Rapid Diagnostic Tests, PCR, Immunoassays, Radioimmunoassay, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20374

North America Hepatitis Testing/Diagnosis Market, 2025–2035

The North America Hepatitis Testing/Diagnosis Market is experiencing significant expansion, primarily driven by increasing hepatitis cases, rising health awareness, supportive regulatory frameworks, and ongoing technology advancements. Diverse testing types, evolving applications, and distribution channels are reshaping the landscape. Major companies are investing in innovative diagnostics, automation, and rapid testing, leading to improved disease management, particularly in healthcare settings. The forecast points to robust growth, with investments in advanced molecular diagnostics and point-of-care solutions likely to dominate the market outlook through 2035.

Latest Market Dynamics

Key Drivers

Rising prevalence of hepatitis B and C infections, particularly in the US and Canada, is driving demand for accurate and rapid diagnostic solutions. For example, Abbott Laboratories introduced new multiplex test panels in 2024, accelerating screening processes and expanding market reach.

Growing adoption of point-of-care rapid testing is leading to faster and more accessible hepatitis diagnosis, especially in non-hospital settings. Siemens Healthineers, for instance, expanded its rapid test portfolio in early 2024.
Integration of digital diagnostics and artificial intelligence (AI) for improved result interpretation and workflow efficiency. Thermo Fisher Scientific launched AI-enabled diagnostic platforms in 2024, enhancing data-driven patient management.

Expanding telemedicine and home-based diagnostic models create opportunities for market players to introduce self-testing kits. In 2024, Bio-Rad Laboratories launched at-home hepatitis C RNA testing solutions.
Growing demand for multiplex testing platforms allows simultaneous screening of multiple hepatitis types, increasing efficiency. Beckman Coulter (Danaher Corporation) recently developed comprehensive panels in partnership with public health labs.

Limited accessibility to advanced diagnostics in rural and underserved regions remains a barrier, affecting early detection rates. Ortho Clinical Diagnostics is piloting mobile lab solutions to address this gap in 2025.
Variability in hepatitis screening recommendations and reimbursement policies across the US, Canada, and Mexico complicates market standardization. Hologic Inc. and partners are working on advocacy campaigns for unified testing protocols.

High cost associated with next-generation molecular testing platforms restricts adoption among small- and medium-sized healthcare organizations. Sysmex Corporation is attempting to address this via cost-efficient models.
Stringent regulatory pathways slow down the approval and commercialization of innovative diagnostic products. QIAGEN faces ongoing regulatory review challenges for its new multiplex assay, delaying entry in the US market.

The North America Hepatitis Testing/Diagnosis Market by type in 2025 is led by Hepatitis B and Hepatitis C testing, together making up the bulk of total market share. Increased awareness, public health initiatives, and rising incidence rates, particularly among high-risk populations, are propelling the demand for these test types. Hepatitis A, D, and E constitute smaller shares, largely due to lower prevalence and targeted vaccination campaigns. The 'Others' segment captures specialized testing and rare hepatitis strains.

In 2025, hospitals & clinics hold the highest share of hepatitis testing/diagnosis applications in North America due to integrated screening programs and robust diagnostic infrastructure. Blood banks follow closely due to mandated routine testing. Diagnostic laboratories and research institutes contribute significant shares as investments in public health and clinical research expand. Public health programs and other applications cover mass screening and targeted initiatives to reach at-risk populations.

Market revenue in North America for hepatitis testing/diagnosis has shown steady growth from 2020, with significant acceleration post-2023 due to new testing technologies and greater healthcare spending. The 2025 market size is projected at 1,220 million USD, with further increases expected as prevention and early detection efforts expand. By 2035, revenue is forecast to reach 2,960 million USD, indicating a CAGR aligned with the sector’s rising health priorities.

The year-on-year (YOY) growth rate of the North America hepatitis testing/diagnosis market demonstrates moderate expansion from 2020–2025, with YOY growth rising from 7.8% in 2021 to a peak of 9% by 2026, driven by improved diagnostics and healthcare frameworks. Growth rates are expected to stabilize between 8–10% through 2035 as innovative products and expanded screening sustain momentum.

In 2025, the regional breakdown of the North America hepatitis testing/diagnosis market shows the US accounting for the dominant share, reflecting its large population, healthcare expenditure, and screening mandates. Canada follows, driven by strong public health programs, while Mexico presents emerging growth through expanded access and awareness campaigns. This distribution underlines the impact of national healthcare strategies and varying disease prevalence across North America.

In 2025, the leading market players in North America Hepatitis Testing/Diagnosis include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, together capturing the majority share as a result of robust portfolios and continuous R&D. Other notable companies such as Bio-Rad Laboratories and Danaher Corporation maintain significant presence with strong technological and strategic advances. Consolidation and innovation are driving performance in this competitive landscape.

Hospitals and clinics form the bulk of buyers in the North America Hepatitis Testing/Diagnosis Market in 2025, reflecting their position as primary care and diagnostic centers. Blood banks, public health agencies, and diagnostic labs are also substantial buyers, driven by regulatory screening requirements and prevention initiatives. The diversification in buyer types demonstrates the widespread need for robust hepatitis diagnostics across North America’s healthcare ecosystem.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1220
Regions	US, Canada, Mexico
Segments	By Type (Hepatitis B, Hepatitis C, Hepatitis A, Hepatitis D, Hepatitis E, Others), By Application (Blood Banks, Hospitals & Clinics, Diagnostic Laboratories, Research Institutes, Others), By Distribution Channels (Direct Tender, Retail Sales, Online Sales, Others), By Technology (ELISA, Rapid Diagnostic Tests, PCR, Immunoassays, Radioimmunoassay, Others), By Organization Size (Small, Medium, Large)
Players	Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories, BioMerieux, Danaher Corporation (Beckman Coulter), QIAGEN, Ortho Clinical Diagnostics, Hologic Inc., Sysmex Corporation, Grifols, Trinity Biotech, Abbott Rapid Diagnostics, Fujirebio, Thermo Fisher Scientific

June 2024: Roche Diagnostics announced a strategic partnership with Canadian public health officials to expand hepatitis C RNA testing access.
July 2024: Bio-Rad Laboratories launched their first at-home hepatitis testing kit across selected US states targeting underserved populations.
August 2024: Siemens Healthineers introduced a digital workflow-integrated rapid hepatitis B surface antigen testing solution.
September 2024: QIAGEN initiated a US multi-center trial for their latest multiplex hepatitis virus screening assay.
October 2024: Danaher Corporation (Beckman Coulter) received FDA clearance for a new all-in-one hepatitis diagnostics panel.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America Hepatitis Testing/Diagnosis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Hepatitis Testing/Diagnosis Market, 2025–2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type, 2025

Market Share by Applications, 2025

Market Revenue (USD Million), 2020–2035

Market YOY (%), 2020–2035

Market Share by Regions, 2025

Market Players Share (%), 2025

Market Buyers Share (%), 2025

Study Coverage

Key Recent Developments

Frequently asked questions